Table 5. Clinical series of cytoreductive surgery for recurrent ovarian cancer.

Author	Study type	Publication year	n (total)	Age (median)	Median overall survival (months)	Disease-free interval (months)	Optimal criteria (cm)	Optimal cytoreduction (%)	Complete cytoreduction (%)
Berek et al9	A	1983	32	54.5	10	6	<1.5	37.5	NA
Morris et al10	A	1989	30	50	16.3	36	<2.0	56.7	30.0
Janicke et al11	A	1992	30	53	18	16	<2.0	86.7	46.7
Segna et al12	A	1993	100	55	16.6	NA	<2.0	61.0	NA
Eisenkop et al13	B	1995	36	60.6	43	22	≤1.0	91.7	83.3
Vaccarello et al14	A	1995	57	57	18	20	<0.5	36.8	17.5
Landoni et al15	A	1998	38	51C (mean)	29	22	No gross	100.0	100.0
Cormio et al16	A	1999	21	58	29	25	<2.0	90.5	71.4
Gadducci et al17	A	2000	30	58.5	21	17.5	<2.0	83.3	56.7
Zang et al18	A	2000	60	50	11	12	≤1.0	38.3	NA
Chen et al19	A	2000	22	56.5	41	26	<1.0	86.4	63.6
Eisenkop et al20	B	2000	106	60.5	35.9	16.8	No gross	82.1	82.1
Munkarah, et al21	A	2001	25	55	25.1	37.6	≤2.0	72	48
Tay et al22	A	2002	46	50.3	22.5	26	≤1.0	71.7	41.3
Bristow et al23	A	2002	21	46	56.2	15.7	≤1.0	71.4	61.9**
Yoon et al24	B	2003	24	47.5	62	36.5	≤1.0	100.0	87.5
Zang et al25	A	2003	60	52	17	NA	≤1.0	38.3	NA
Meredith et al26	A	2003	26	62	26.3	23.4	≤1.0	80.8	69.2
Look et al27	A	2003	24	54	45.8	NA	<2.5	87.5	20.8
Loizzi et al28	D	2003	31	57	38	34	<2.0	90.3	NA
Leitao et al29	A	2004	26	55.5	33.4	13.4	≤0.5	73.1	53.8
Zang et al30	B	2004	117	53	22	15.4	≤1.0	61.5	9.4
Zanon et al31	B	2004	30	60	28.1	NA	≤0.25	76.7	NA
Uzan et al32	A	2004	12	51	50	21	No gross	100.0	100.0
Gronlund et al33	B	2005	38	59C	27.4E	16.3	No gross	42.1	42.1
Gungor et al34	A	2005	44	54.3	16	27.1	<1.0	77.3	NA
Yap et al35	A	2005	22	57.4	26	48.2	<0.5	100.0	NA
Onda et al36	B	2005	44	52	32	18.5	<1.0	84.1	59.1
Ayhan et al37	A	2006	64	50.6	18.6	15.5	≤1.0	82.8	43.8
Matsumoto et al38	A	2006	23	55.7	41.7	22.5	<2.0	43.4	30.4
Manci et al39	A	2006	24	54	56	26	≤0.5	100.0	66.7
Chi et al40	A	2006	153	56.5	41.7	NA	≤0.5	51.6	40.5
Harter et al41	B	2006	267	60	29.2	NA	≤1.0	75.7	49.8
Rufian et al42	B	2006	14	55	57	NA	≤1.0	85.0	52.0
Helm et al43	A	2007	18	64	31	24.6	≤0.5	94.4	61.1
Salani et al44	A	2007	55	57.7	48	26	≤1.0	89.1	74.5
Santillan et al45	A	2007	25	59	37	16	≤1.0	100.0	96.0
Benedetti Panici et al46	B	2007	40	51	60C	14	No gross	72.5	72.5
Benedetti Panici et al47	B	2007	47	52	49	15	≤1.0	87.2	78.7
Cotte et al48	B	2007	81	54.3	28.4	NA	≤0.5	80.2	55.6
Tebes et al49	A	2007	85	61 (mean)	30	39 (mean)	<1.0	86	NA
Fotiou et al50	A	2009	21	50	47	21	≤1.0	90.5	81
Bae et al51	A	2009	54	54	42	24	≤0.5	87	59.3
Cheng et al52	A	2009	21	53	27	14	≤1.0	33	NA
Bristow et al53	A	2009	56	56	38.4	NA	≤1.0	92.9	85.7
Fagotti et al54	B	2009	25	52	C	25	<0.25	NA	92
Harter et al55	A	2009	250	60	29.5	NA	≤1.0	NA	50
Park et al56	A	2010	67			20			55.2
Tian et al57	A	2010	125	51	31.7	16.1	≤1.0	78.9	41.5
Sehouli et al58	B	2010	240	57	29	NA	≤1.0	77.9	53.8
Woelber et al59	A	2010	48	60	26	18	<1.0	47.9	33.3
Schorge et al1	A	2010	40	55.4	54	28	<0.5	80	55
Fagotti et al60	B	2011	41	52.6	38	19	<0.25	100.0	100.0
Frederick et al61	A	2011	62	52.7		28.2	<1.0	40.3	36
Burton et al62	A	2011	20	59	22.5	18	No gross	NA	55
Königsrainer et al63	A	2011	31	60	1150 days	762 days	No gross	90.3	65
Classe et al64	A	2011	35	58.5	35	40	<1.0	60	34.3
Ceelen et al65	B	2012	42	52	37	3	No gross	NA	50

NA:data not available; A: retrospective review; B: prospective, non-randomized; C: median not yet reached; D: retrospective case-control; E: personal communication.